A Novel Blood Index-Based Model to Predict Hepatitis B Virus-Associated Hepatocellular Carcinoma Recurrence After Curative Hepatectomy: Guidance on Adjuvant Transcatheter Arterial Chemoembolization Choice

Zou, Yiping; Lou, Qi; Han, Hongwei; Zhang, Yuanpeng; Chen, Zhenrong; Ma, Zuyi; Shi, Ning; Jin, Haosheng

doi:10.3389/fonc.2021.755235

Cited by 5 publications

(7 citation statements)

References 35 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We therefore selected 200 for subgroup analysis of sample size. Four studies treated patients with HCC with surgery ( 18 , 21 , 22 , 27 ), two studies used TACE treatment ( 20 , 26 ), and one each used sorafenib ( 19 ), radiofrequency ablation (RFA) ( 23 ), sorafenib/immune checkpoint inhibitors (ICIs) ( 24 ), and LT ( 25 ). Nine studies were single-center studies ( 18 , 19 , 21 – 27 ) and one was a multicenter study ( 20 ).…”

Section: Resultsmentioning

confidence: 99%

“…We, therefore, used 1.1 for subgroup analysis of cut-off value in the following analyses. Nine articles used the receiver operating characteristic (ROC) curve to determine the best threshold ( 18 – 22 , 24 – 27 ) and one study applied the X-tile software ( 23 ). Six studies reported the significance of SIRI in the OS prediction of HCC ( 18 – 20 , 23 – 25 ) and eight studies reported the association between SIRI and PFS ( 20 – 27 ).…”

Section: Resultsmentioning

confidence: 99%

“…Six studies reported the significance of SIRI in the OS prediction of HCC ( 18 – 20 , 23 – 25 ) and eight studies reported the association between SIRI and PFS ( 20 – 27 ). Six studies reported HRs and 95%CIs using multivariate analysis ( 18 , 21 , 22 , 25 – 27 ) and four studies used univariate analysis ( 19 , 20 , 23 , 24 ). The NOS scores of all eligible studies were 7–9, suggesting a high quality ( Table 1 ).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Prognostic and clinicopathological significance of systemic inflammation response index in patients with hepatocellular carcinoma: a systematic review and meta-analysis

Zhang,

Tang

2024

Front. Immunol.

View full text Add to dashboard Cite

BackgroundIt is unclear whether the systemic inflammation response index (SIRI) can predict the prognosis of patients with hepatocellular carcinoma (HCC). Consequently, the present study focused on systematically identifying the relationship between SIRI and the prognosis of patients with HCC through a meta-analysis.MethodsSystematic and comprehensive studies were retrieved from PubMed, Web of Science, Embase, and the Cochrane Library from their inception to August 10, 2023. The role of SIRI in predicting overall survival (OS) and progression-free survival (PFS) in HCC was determined using pooled hazard ratios (HRs) and 95% confidence intervals (CIs). Odds ratios (ORs) and 95% CIs were pooled to analyze the correlations between SIRI and the clinicopathological features of HCC.ResultsTen articles involving 2,439 patients were included. An elevated SIRI was significantly associated with dismal OS (HR=1.75, 95% CI=1.52–2.01, p<0.001) and inferior PFS (HR=1.66, 95% CI=1.34–2.05, p<0.001) in patients with HCC. Additionally, according to the combined results, the increased SIRI was significantly related to multiple tumor numbers (OR=1.42, 95% CI=1.09–1.85, p=0.009) and maximum tumor diameter >5 cm (OR=3.06, 95% CI=1.76–5.30, p<0.001). However, the SIRI did not show any significant relationship with sex, alpha-fetoprotein content, Child-Pugh class, or hepatitis B virus infection.ConclusionAccording to our results, elevated SIRI significantly predicted OS and PFS in patients with HCC. Moreover, the SIRI was significantly associated with tumor aggressiveness.Systematic review registrationhttps://inplasy.com/inplasy-2023-9-0003/, identifier INPLASY202390003.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic and clinicopathological significance of systemic inflammation response index in patients with hepatocellular carcinoma: a systematic review and meta-analysis

Zhang,

Tang

2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…24 We confirmed that MVI was an independent risk factor in this study, which is consistent with our previous findings. 25,26 Our previous studies have demonstrated that receiving adjuvant TACE or HAIC with FOLFOX after hepatectomy might improve the RFS and OS for HCC patients with MVI, and the adverse events were evaluated as mild and manageable. 10,11 SIRI and ANRI are both comprehensive haematological indices of inflammation.…”

Section: Discussionmentioning

confidence: 99%

Nomogram Based on Inflammatory Biomarkers to Predict the Recurrence of Hepatocellular Carcinoma—A Multicentre Experience

Zheng¹,

Guan²,

Zou³

et al. 2022

JIR

Self Cite

View full text Add to dashboard Cite

Our study aimed to identify inflammatory biomarkers and develop a prediction model to stratify high-risk patients for hepatitis B virus-associated hepatocellular carcinoma (HBV-HCC) recurrence after curative resection. Patients and Methods: A total of 583 eligible HBV-HCC patients with curative hepatectomy from Guangdong Provincial People's Hospital (GDPH) and Sun Ya-sen University Cancer Centre (SYSUCC) were enrolled in our study. Cox proportional hazards regression was utilized to evaluate potential risk factors for disease-free survival (RFS). The area under the receiver operating characteristic (ROC) curve (AUC) was utilized to assess the discrimination performance. Calibration plots and decision curve analyses (DCA) were used to evaluate the calibration of the nomogram and the net benefit, respectively. Results: Based on the systemic inflammation response index (SIRI), aspartate aminotransferase to neutrophil ratio index (ANRI), China Liver Cancer (CNLC) stage and microvascular invasion, a satisfactory nomogram was developed. The AUC of our nomogram for predicting 1-, 2-, and 3-year RFS was 0.767, 0.726, and 0.708 in the training cohort and 0.761, 0.716, and 0.715 in the validation cohort, respectively. Furthermore, our model demonstrated excellent stratification as well as clinical applicability. Conclusion:The novel nomogram showed a higher prognostic power for the RFS of HCC patients with curative hepatectomy than the CNLC, AJCC 8th edition and BCLC staging systems and may help oncologists identify high-risk HCC patients.

show abstract

“… 18 , 23 , 24 Moreover, some models predicting recurrence after PA-TACE for HBV-HCC patients have been developed. 25 , 26 Yet, there is no commendable evaluation system to predict the OS of HBV-HCC who have had PA-TACE directly; therefore, in certain situations, it is difficult for clinicians to decide on initiating PA-TACE, especially for individuals without any significant recurrence risk factors.…”

Section: Introductionmentioning

confidence: 99%

Development and Validation of a Prediction Model for Hepatitis B Virus-Related Hepatocellular Carcinoma Patients Receiving Postoperative Adjuvant Transarterial Chemoembolization

Tu,

Zhang,

et al. 2023

JHC

View full text Add to dashboard Cite

Background Hepatocellular carcinoma (HCC) patients who are at significant risk of tumor recurrence and mortality can benefit from postoperative adjuvant transarterial chemoembolization (PA-TACE). However, the benefits of PA-TACE remain unclear. Herein, we aimed to develop a model for predicting the prognosis of HBV-related patients who undergo PA-TACE and endeavored to guide individualized clinical treatment. Methods We included 432 HBV-related patients who underwent PA-TACE after curative resection were included. The dataset was divided into a training set (n=216) and an internal validation set (n=216). For identifying independent risk factors, the least absolute shrinkage and selection operator and univariate and multivariate Cox analyses were performed. We derived a prognostic model from the training set that was internally validated. The concordance index (C-index), receiver operating characteristic (ROC) curve, calibration curve, and risk stratification were used to evaluate the performance of the nomogram. Results Patients undergoing PA-TACE had significantly longer overall survival (OS) than those who did not undergo PA-TACE. Age, albumin levels, macrovascular invasion, tumor size, and, stages of Barcelona Clinic Liver Cancer were identified as independent risk variables and concluded into the nomogram to predict the OS of HBV-related patients who received PA-TACE. The nomogram’s C-index values OS were 0.710 and 0.652 in the training and internal validation sets, respectively. Both time-dependent AUC and the calibration curve showed good discrimination and model fitness. The risk score −0.12 was kept as the cut-off value that would accurately divide patients into high-risk and low-risk groups; furthermore, the Kaplan–Meier curve showed a high discriminative ability of the model. Conclusion We developed a predictive model. comprising a formula and nomogram to predict the OS and provide risk stratification for HBV-related patients undergoing PA-TACE, which could contribute to suitable treatment options for this patient population.

show abstract

A Novel Blood Index-Based Model to Predict Hepatitis B Virus-Associated Hepatocellular Carcinoma Recurrence After Curative Hepatectomy: Guidance on Adjuvant Transcatheter Arterial Chemoembolization Choice

Cited by 5 publications

References 35 publications

Prognostic and clinicopathological significance of systemic inflammation response index in patients with hepatocellular carcinoma: a systematic review and meta-analysis

Prognostic and clinicopathological significance of systemic inflammation response index in patients with hepatocellular carcinoma: a systematic review and meta-analysis

Nomogram Based on Inflammatory Biomarkers to Predict the Recurrence of Hepatocellular Carcinoma—A Multicentre Experience

Development and Validation of a Prediction Model for Hepatitis B Virus-Related Hepatocellular Carcinoma Patients Receiving Postoperative Adjuvant Transarterial Chemoembolization

Contact Info

Product

Resources

About